By Nicholas J Silvestri and
Jacqueline A Palace
48 pages, 9 illustrations
$25.00 (Our delivery cost is a flat fee of $9.00 so the more you order the better!)
An in-depth look at a rare disease
Myasthenia gravis (MG) is a rare autoimmune disorder of the neuromuscular junction, characterized by muscle fatigability. Patients often initially present with ocular symptoms, but in most cases the disease spreads beyond the eye muscles to more generalized involvement of bulbar, facial, neck, proximal limb and respiratory muscles. With adequate treatment, most patients with MG are able to live productive lives with few or no symptoms, but a distinct subset of patients do not respond to conventional treatment. With new treatment options on the horizon, it is important that these patients are identified.
Fast Facts: Recognizing Refractory Myasthenia Gravis takes an in-depth look at:
This informative resource will be of value to neurologists, neurology trainees and ophthalmologists caring for patients with this rare disease, as well as patients with MG who wish to have a deeper dialog with their doctor or patient group.
“ ... clearly written and full of useful information about this much misunderstood condition.”
Ruth Ingledew, Chief Executive Officer, myaware
“A good concise summary of refractory generalized myasthenia gravis, from two neurologists with high expertise in this field.”
Professor Rudolf Janzen, German Myasthenia Gravis Association
Nicholas J Silvestri
Clinical Associate Professor of Neurology, Jacobs School of Medicine and Biomedical Sciences; Department of Neurology, Buffalo General Hospital
Jacqueline A Palace
Consultant Neurologist, Nuffield Department of Clinical Neurosciences, Oxford
Are you a healthcare professional?
Have you taken the FastTest for this title?
Thank you for your feedback
Feel free to leave a comment for the authors below.
If you haven't already, don't forget to take the FastTest for this title.
Janzen R.W.C., Germany 04 Apr 2018
concerning Fig.4.1 is a good platform für the early phase. The problem is the optimal individual step for "escalation" of aggressive treatment. My opinion would be: after adequate azathioprine change to mycophenolate mofetil, my be ciclosporine, there after think for rituximab. May be there should be a Fig. 4.2 ?
Good health decisions